Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.09)
# 2,879
Out of 4,944 analysts
55
Total ratings
36.73%
Success rate
-1.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $18.74 | +246.85% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $9.52 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $17.41 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.64 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $30.88 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.72 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $5.23 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $3.65 | +173.97% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $359.00 | - | 4 | Nov 20, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $54.84 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $48.03 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.90 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $27.12 | -11.50% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.45 | +18,267.35% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.93 | +1,398.77% | 1 | Mar 3, 2021 |
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $18.74
Upside: +246.85%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.52
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.41
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.64
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $30.88
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $13.72
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.23
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $3.65
Upside: +173.97%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $359.00
Upside: -
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.84
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $48.03
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.90
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $27.12
Upside: -11.50%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.45
Upside: +18,267.35%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.93
Upside: +1,398.77%